Author
Listed:
- Karel H. Pol
(Radboud University Medical Center)
- Mohamad Aljofan
(Nazarbayev University School of Medicine
National Laboratory Astana, Nazarbayev University)
- Olivier Blin
(Aix Marseille Université, Inserm UMR 1106)
- Jan H. Cornel
(Radboud University Medical Center
Northwest Clinics)
- Gerard A. Rongen
(Radboud University Medical Center)
- Aurélie-Gaëlle Woestelandt
(Spedding Research Solutions SAS)
- Michael Spedding
(Spedding Research Solutions SAS)
Abstract
Drug repurposing is the process of identifying a new use for an existing drug or active substance in an indication outside the scope of the original indication. Drug repurposing has important advantages including reduced development time and costs, and potentially large societal healthcare cost savings. However, current generic drug repurposing research faces a number of challenges in obtaining research funds. Furthermore, regardless of the success of a repurposing trial, commercial parties often lack interest in pursuing marketing authorisation for financial reasons, and academic researchers lack the knowledge, time and funding. Therefore, the new indication of a repurposed drug often does not make it ‘on label’. We propose a large increase in public funding for generic drug repurposing research, including funds for the marketing authorisation process when a trial is successful, and a reduction in the regulatory burden of the marketing authorisation process for repurposed generic drugs.
Suggested Citation
Karel H. Pol & Mohamad Aljofan & Olivier Blin & Jan H. Cornel & Gerard A. Rongen & Aurélie-Gaëlle Woestelandt & Michael Spedding, 2023.
"Drug Repurposing of Generic Drugs: Challenges and the Potential Role for Government,"
Applied Health Economics and Health Policy, Springer, vol. 21(6), pages 831-840, November.
Handle:
RePEc:spr:aphecp:v:21:y:2023:i:6:d:10.1007_s40258-023-00816-6
DOI: 10.1007/s40258-023-00816-6
Download full text from publisher
As the access to this document is restricted, you may want to search for a different version of it.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:aphecp:v:21:y:2023:i:6:d:10.1007_s40258-023-00816-6. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.